Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Instil Bio Inc TIL

Instil Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies. The Company seeks to in-license/acquire and develop novel therapeutic candidates in diseases with significant unmet medical need. Its first such program is an engineered tumor infiltrating lymphocyte (TIL), cell therapy for the treatment of cancer. It is engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor (CoStAR), platform. The Company's lead CoStAR-TIL product candidate, ITIL-306, expresses a CoStAR molecule designed to recognize folate receptor alpha (Fra), a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC and renal cancer. CAR-T and TCR-T therapies are cell products composed of T cells that have been genetically engineered to recognize a specific cancer-related antigen on the surface of tumor cells.


NDAQ:TIL - Post by User

Bullboard Posts
Post by _mvmon May 27, 2006 11:58am
158 Views
Post# 10911864

Observation on insider buying

Observation on insider buyingLots of negative comments on this board right now. I can't blame anyone. I don't see an end in sight and am perfectly happy sitting on the sidelines for a while longer. I would suggest that this company is not without value though. At some point I will jump back in as well but I can't see it being wise until well after the reverse split. Once the reverse split is done this will look a lot healthier, a company with some promising new and existing products solidly tanked on account of a series of moves that made perfect business sense but were absolutely idiotic from an investment point of view. IMO the market will continue to punish them until the reverse split is done and it will take some time after before people start assessing what is really there and realizing that it may all have some value. Some insider buying ahead of it all, pretty small but still a show of confidence. May 26/06 May 26/06 Mäder, Hans J. 10 - Acquisition in the public market Common Shares 10,000 $0.190 May 24/06 May 23/06 de Rougé, Bonabes-Olivier 10 - Acquisition in the public market Common Shares 10,000 $0.210 May 23/06 May 19/06 de Rougé, Bonabes-Olivier 10 - Acquisition in the public market Common Shares 10,000 $0.215
Bullboard Posts